urine to kidney biomarkers for drug safety · 2017-03-24 · our kidney toxicity biomarker services...
TRANSCRIPT
Nextcea simultaneously detects multiple protein biomarkers in urine samples to monitor the onset and time-course of toxicity. No antigen-antibody labeling is required. Nextcea has developed specific and sensitive assays to quantitate these proteins in a single run by UPLC-MS/MS.
Kidn
ey B
iom
arke
rs fo
r Dru
g Sa
fety
Nextcea
Kidney Injury Protein Biomarker Assays in Monkeys and in Humans (GLP and non-GLP)
Safety Assessment by UPLC/MS/MS AnalysisThese renal toxicity protein biomarkers (KIM-1, β2-microglobulin, clusterin, trefold factor 3, cystatin C, and lipocalin-2) have been shown to provide higher sensitivity than traditional biomarkers BUN, NAG, and serum creatinine. The location and sequence of kidney damage is determined non-invasively based on levels of these proteins over time.
Our kidney toxicity biomarker services non-invasively monitor kidney damage across species. The assay detects biomarkers resulting from both drug-induced and disease-affected kidney damage. Nextcea monitored the following biomarkers by UPLC/MS/MS in urine from rats treated with gentamicin, a compound known to cause kidney toxicity.
ureter
• KIM-1• Clusterin• Trefoil Factor 3• Cystatin C• β2-microglobulin• Lipocalin-2
Nextcea measures FDA/EMEA kidney toxicity
protein biomarkers in a single UPLC/MS/MS
analysisKidney
Urine to
Renal corpuscle
Loop of Henle
Proximal tubuleDistal tubule
Collecting duct
0
500
1000
1500
2000
2500
Vehicle Gentamicin
KIM-1
Biom
arke
r In
tens
ity
0
5000
10000
15000
20000
25000
Vehicle Gentamicin
Cystatin C
Biom
arke
r In
tens
ity
0
50000
100000
150000
200000
250000
300000
350000
400000
Gentamicin
Lipocalin-2Bi
omar
ker
Inte
nsity
0
500
1000
1500
2000
2500
3000
3500
4000
Vehicle Gentamicin
Clusterin
Biom
arke
r In
tens
ity
0
2000
4000
6000
8000
10000
12000
14000
Vehicle Gentamicin
Vehicle
Biom
arke
r In
tens
ity
About Nextcea, Inc.Nextcea, Inc. is a drug development service company dedicated to optimizing efficacy and minimizing toxicity in all phases of drug development. Nextcea integrates cross-species biomarker studies with traditional PK/PD and TK/TD. In-house platforms include HPLC/UPLC coupled to mass spectrometry LC-MS and LC-MS/MS (API-6500s and and TripleTOF 6600).
β2-microglobulin
Hirohide Mimura (三村博英):[email protected]
500 W. Cummings Park, #4550 Woburn, MA 01801
781-457-4010